Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.

Inclusion criteria

• Patients must suffer from RA, and must have participated in the preceding study.
• Patients must have been confirmed to be appropriate on week 52 of the preceding study by X radiography.

Exclusion criteria

• Patients evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug
• Patients who have not been registered by 3 months after week 52 of the preceding study